Delaware
|
|
000-29169
|
|
98-0178636
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S
Employer Identification No.)
|
33
Harbour Square, Suite 202, Toronto, Ontario Canada
|
|
M5J
2G2
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
(d)
|
Exhibits.
|
Exhibit
Number
|
Description
|
|
10.1
|
At
Market Issuance Sales Agreement, dated October 14, 2009, by and
between Generex Biotechnology Corporation and Wm. Smith &
Co.
|
GENEREX
BIOTECHNOLOGY CORPORATION.
|
||||||
Date:
October 14, 2009
|
/s/
Rose C. Perri
|
|||||
Chief
Operating Officer and Chief Financial
Officer
(principal
financial officer)
|
Exhibit
Number
|
Description
|
|
10.1
|
At
Market Issuance Sales Agreement, dated October 14, 2009, by and
between Generex Biotechnology Corporation and Wm. Smith &
Co.
|